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depression was already conﬁrmed.2 Moreover, it may predis-
pose patients to consider withdrawal of dialysis. We performed
a cross-sectional study (n¼ 205) evaluating the prevalence of
pain among a cohort of long-term HD patients and compared
depression (Hospital Anxiety and Depression Scale (HADS))
and quality of life (Version 2.0 of Short Form 36 (SF-36)) in
patients with and without chronic pain.3 The results are
summarized in Table 1. Signiﬁcant differences were found in
anxiety (HADS-A), depression (HADS-D), and all SF-36 scales.
Patients with pain showed higher levels of calcium-phosphorus
ion product and parathyroid hormone than those without pain.
Perhaps those with pain and depression are more non-adherent
to dietary and ﬂuid restriction, which in turn may lead to worse
outcomes in the future.4 Data on pain prevalence or even the
subanalysis in the study by the Duarte group would be
interesting. Some data about pain are in KDQOL-SF (body
pain).
While investigating the problem of how to create coping
strategies to deal with dialysis treatment, depression, and pain,
we found in our study some differences between patients who
were on the waiting list for kidney transplantation and those
who were not on the list (Traﬁdło et al.; www.abstracts2view.
com/wcn). HD patients with chronic pain evidenced that being
on the waiting list was associated with diminished cognitive/
behavioral scores in the Pain Coping Strategies Questionnaire
(less catastrophizing; P¼ 0.009). A similar comparison addres-
sing depression-coping strategies would be important.
Finally, we appreciate Duarte et al. for the ﬁrst randomized
trial on CBT in the HD population and also encourage
nephrologists to pay more attention to diagnosing and
treating depression in HD patients because it may be essential
in pain management.
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The Authors Reply: We appreciate the interest in our
recently published article ‘Cognitive-behavioral group therapy
is an effective treatment for major depression in hemodialysis
(HD) patients’, which presented the advantages of a speciﬁc
psychological approach to treat depression in Brazilian
patients undergoing hemodialysis.1,2 The authors recognize
the importance of studying in more depth the relationship of
physical symptoms, such as pain, in chronic kidney disease
and its treatment, with both the functional status and the
psychosocial well-being of these patients.
The prevalence of chronic pain in patients of our study
was high. At the beginning of the study, the percentage of
patients with body pain was similar in the two study groups:
84.8% (n¼ 39) in the cognitive-behavioral therapy group
and 84.1% (n¼ 37) in the control group. After 3 months,
this prevalence rate decreased in the intervention group
(78.0% (n¼ 32)) and increased in the control group (88.6%
(n¼ 39)). Muscle pain was present in 71.7% (n¼ 33) and
72.7% (n¼ 32) of the patients in the intervention and the
control groups, respectively, at baseline. The corresponding
ﬁgures after 3 months of study were 73.2 and 72.7%,
respectively. Seventy-two percent (n¼ 33) of the patients in
the intervention group and 72.7% (n¼ 32) of the patients in
the control group stated at baseline that the pain interfered
Table 1 | A comparison of HD patients with and without pain
No pain
(n=75)
Chronic pain
(n=130)
ANOVA
Mean s.d. Mean s.d. P
Maintenance HD (months) 36.1 43.3 64.9 67.8 0.0011
Age (years) 62.7 14.1 58.9 13.6 0.0598
24 h diuresis (l) 0.5 0.5 0.3 0.5 0.0065
BMI 25.0 4.1 25.4 4.2 0.4855
SBP before HD (mmHg) 136.4 26.5 133.8 24.7 0.4797
DBP before HD (mmHg) 77.7 11.0 76.0 11.2 0.3014
SBP after HD (mmHg) 131.3 25.7 126.6 26.4 0.2175
DBP after HD (mmHg) 75.5 11.9 73.8 12.3 0.3368
Total protein (g/l) 6.9 0.6 7.0 0.6 0.1406
Albumin (g/l) 3.6 0.4 3.7 0.5 0.1526
Hemoglobin (g/l) 10.6 1.6 11.1 2.8 0.2135
CaxP 47.2 17.1 53.1 17.3 0.0190
PTH 215.6 181.6 467.0 595.9 0.0004
kt/V 1.1 0.2 1.2 0.3 0.1710
kt/V weekly 3.4 0.6 3.5 0.6 0.1543
Mean UF 2610.7 857.9 2706.9 844.7 0.4354
CRP (g/l) 12.1 15.0 14.2 23.7 0.4990
HADS-A 4.3 3.4 6.5 3.4 0.0000
HADS-D 4.6 4.0 6.8 4.1 0.0002
MMSE 25.6 3.1 27.2 7.5 0.2559
SF-36v2
GH 49.1 19.6 38.4 17.7 0.0001
BP 86.8 22.0 44.5 25.6 0.0000
PF 52.6 31.7 36.6 29.8 0.0004
RP 57.4 44.3 40.5 43.1 0.0088
RE 70.8 42.6 58.5 45.4 0.0624
VT 59.2 22.4 44.1 19.7 0.0000
MH 69.9 19.2 59.2 20.6 0.0003
SF 77.4 26.0 59.5 28.4 0.0000
Abbreviations: ANOVA, analysis of variance; BMI, body mass index; BP, bodily pain;
CaxP, calcium-phosphorus ion product; CRP, C-reactive protein; DBP, diastolic blood
pressure; GH, general health; HADS, Hospital Anxiety and Depression Scale; HD,
hemodialysis; MH, mental health; MMSE, Mini-Mental State Examination; PF, physical
functioning; PTH, parathyroid hormone; RE, role-emotional limitation; RP, role-physical
limitation; SBP, systolic blood pressure; SF, social functioning; SF-36v2, Version 2.0 of
Short Form 36; UF, ultrafiltration; VT, vitality.
The bold values indicate statistically significant difference (Po0.05).
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with their normal work. After 3 months, these percentages
changed to 58.5 and 81.8% in the cognitive-behavioral
therapy (CBT) and control groups, respectively.
The relationship between pain and depression in end-stage
renal disease patients is important. The impact of CBT in
alleviating body pain in these patients requires future research.
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Sudden cardiac death and mineral
metabolism in chronic kidney
disease
Pun et al. showed that reductions in the estimated glomerular
ﬁltration rate (eGFR) were associated with an increase in the
risk of sudden cardiac death in a graded fashion in patients
with coronary artery disease. The authors claimed that
decreased eGFR induces many metabolic and physiological
changes that might be responsible for increased sudden
cardiac death in chronic renal failure patients.1 Although the
study is informative, we are especially concerned about the
relationship between calcium, phosphorus, Ca P product,
parathyroid hormone levels, and sudden cardiac death in the
study population. It is well established that abnormalities in
mineral metabolism are apparent early in the course of
chronic kidney disease (CKD). Beginning in CKD stage 3, the
ability of the kidneys to appropriately excrete a phosphate
load is diminished, leading to hyperphosphatemia, elevated
parathyroid hormone, and decreased vitamin D levels.
Furthermore, there is emerging evidence linking some of
these abnormalities (for example, hyperphosphatemia and
hypercalcemia) to the high cardiovascular morbidity and
mortality experienced by nondialyzed patients with CKD.
One of the mechanisms for deranged mineral metabolism
to induce cardiovascular disorders is thought to be the
calciﬁcation of the vascular tree that result in arterial stiffness.
Arterial stiffness of the large arteries has important clinical
consequences: raised systolic blood pressure, increased pulse
pressure, left ventricular hypertrophy, and reduced coronary
perfusion.2,3
Experimental evidence showed that high levels of phos-
phate and/or calcium directly activated genes related to an
osteoblastic phenotype in the smooth muscle cells.4 In
addition, elevated phosphorus and calcium stimulated the
transformation of vascular smooth muscle cells into osteo-
blast-like cells in vitro using cell-culture techniques.5 Besides,
clinical evidence also suggests that high pre-dialysis serum
phosphate is a powerful predictor of sudden cardiac death.6
Since the regular control of calcium, phosphorus, and
parathyroid hormone in chronic renal failure patients is
strongly recommended, if available, the presently informative
results by Pun et al. would have been much more valuable
with the addition of parameters of mineral metabolism in the
adjusted analyses.
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The Authors Reply: We appreciate Drs Afsar and Elsurer
for their interest and comments about our study.1 We agree
that disordered mineral metabolism has been associated
with cardiac risk in hemodialysis patients,2 in those with less
severe chronic kidney disease,3 and in some patients who
lack overt kidney disease.4 We now report available laboratory
data on serum calcium, phosphorus, and parathyroid
hormone (PTH) concentrations obtained within 3 months
prior to cardiac catheterization in the study cohort.
Concurrent PTH data were unavailable on the majority of
patients, but calcium and phosphorus data were available in
46% of patients with glomerular ﬁltration rate (GFR) o15
and in 18% of patients with GFRX15 (Table 1). Calcium and
calcium–phosphorus product had no signiﬁcant relationship
with the composite outcome, but phosphorus had a
signiﬁcant relationship (hazard ratio 1.27, 95% conﬁdence
interval 1.04–1.55) in univariate analysis. However, this
relationship was abolished after accounting for baseline
GFR. Accounting for serum phosphorus did not alter the
relationship between GFR and outcome in an adjusted model.
Therefore, our study ﬁndings could not be explained by
measured abnormalities in mineral metabolism, although the
analysis was limited by missing data.
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